Regeneron’s head of COA and Patient Innovation, Rinol Alaj, is to contribute to the 5th Annual Sensors, Wearables and Digital Biomarkers in Clinical Trials conference with a case study that included Moticon’s sensor insoles and its lately launched ReGo product line. The talk is scheduled on Wednesday February 9th 2022 at 9:24 am.
Regeneron will share, according to the conference program, how the company is leveraging the advancement and adoptability of consumer health monitors to further their goals of finding, developing and validating digital endpoints. The session will provide an overview of the different stages of digital endpoint validation the company used through a case study.
For the study in scope, Moticon facilitated mobile gait and balance data acquisition on patients in a multi-center setting with several clinics participating in the trial. Before, Regeneron had evaluated Moticon’s sensor insole technology in smaller trials internally since 2018 and moved on to larger scopes when Moticon’s gait data proved consistent. To meet Regeneron’s stakes, Moticon built customized patient outcome assessment modules for its new ReGo ecosystem which rests on highly structured and automated movement tests. The ReGo tests facilitate seamless and complete patient assessments as they also include patient reported outcome measures in addition to the objective, sensor based metrics.
The conference, says its website, is designed to feature case studies of clinical trials that already employ sensors and wearables, as well as to discuss the future steps needed for implementation of digital biomarkers and endpoints in clinical trials.
